Lupin jumps on launching Lapatinib Tablets

01 Oct 2020 Evaluate

Lupin is currently trading at Rs. 1013.85, up by 6.75 points or 0.67% from its previous closing of Rs. 1007.10 on the BSE.

The scrip opened at Rs. 1029.70 and has touched a high and low of Rs. 1029.70 and Rs. 1007.00 respectively. So far 43760 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 1029.70 and Rs. 978.75 respectively. The current market cap of the company is Rs. 45967.63 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.88% and 12.91% respectively.

Lupin has launched Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma received final approval for its ANDA from the United States Food and Drug Administration (USFDA). Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation. Lapatinib Tablets (RLD: Tykerb) had annual sales of approximately $61 million in the U.S. (IQVIA MAT June 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2071.35 -26.30 (-1.25%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×